May 14, 2024, 10:35
RELATIVITY-060 – summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University shared a post on X:
“Adding relatlimab to nivolumab+ ChT in first line treatment of advanced gastric and Gastroesophageal junction (GEJ) cancer
RELATIVITY-060 at Journal of Clinical Oncology.
Negative study
- ORR: 48% vs 61%
- mPFS: 7.0 vs 8.3 mo, HR: 1.41 (0.97 to 2.05)
- mOS: 13.5 vs 16.0 mo, HR, 1.04: (0.70 to 1.54).”
Additional information.
Source: Erman Akkus/X
